3003新葡的京集团
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2023.03.30
3003新葡的京集团:2022年度监事会工作报告
2023.03.30
3003新葡的京集团:独立董事提名人声明(吕川)
2023.03.30
3003新葡的京集团:独立董事候选人声明(吕川)
2023.03.30
3003新葡的京集团:独立董事对担保等事项的独立意见
2023.03.30
3003新葡的京集团:2022年度财务决算报告
2023.03.29
3003新葡的京集团:深圳市3003新葡的京集团药业集团股份有限公司2022年面向专业投资者公开发行公司债券2023年...
2023.03.28
3003新葡的京集团:关于子公司签订许可协议的公告
2023.03.17
3003新葡的京集团:关于依诺肝素钠注射液获得美国药品注册批件的公告
2023.02.24
3003新葡的京集团:深圳市3003新葡的京集团药业集团股份有限公司关于“203003新葡的京集团”回售结果暨摘牌公告
2023.02.24
3003新葡的京集团:深圳市3003新葡的京集团药业集团股份有限公司2020年面向合格投资者公开发行公司债券(疫情...
第一页
上一页
11
12
13
14
15
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.